Peptide Schedule
Pemvidutide (ALT-801)Small moleculeNo amino acid sequence. Icon reflects category theme only.Pemvidutide (ALT-801) Dosage Calculator
Pemvidutide (ALT-801) is a dual GLP-1 and glucagon receptor agonist developed by Altimmune for obesity and MASH (metabolic dysfunction-associated steatohepatitis).
1.2mcg · Weekly
Summary: Add 0mL BAC water to your 5mg vial. Draw to < 0.1 units on a U-100 syringe for a 1.2mcg dose. This vial will last 0 doses.
Cycle Planner
Pemvidutide (ALT-801) Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~4-6 days (estimated)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Pemvidutide (ALT-801) Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 1.2mg | Weekly |
| Moderate | 1.8mg | Weekly |
| Aggressive | 2.4mg | Weekly |
Note: Dual GLP-1/glucagon receptor agonist by Altimmune. Phase 2 data shows 15.6% weight loss and up to 78.6% liver fat reduction at 2.4mg weekly. No dose titration required in trials, though starting at 1.2mg is recommended. Pre-filled pen format used in clinical trials.
About Pemvidutide (ALT-801)
Pemvidutide (ALT-801) is a dual GLP-1 and glucagon receptor agonist developed by Altimmune for obesity and MASH (metabolic dysfunction-associated steatohepatitis). Unlike GLP-1-only drugs such as semaglutide, pemvidutide activates both the GLP-1 receptor and the glucagon receptor in a balanced 1:1 ratio. This dual mechanism means it suppresses appetite through GLP-1 activity while simultaneously increasing hepatic fat oxidation and energy expenditure through glucagon receptor activation — a combination that drives both weight loss and direct liver fat reduction. The Phase 2 MOMENTUM trial (48 weeks, 391 participants with obesity) showed dose-dependent weight loss: 10.3%, 11.2%, and 15.6% at the 1.2mg, 1.8mg, and 2.4mg weekly doses respectively, compared to 2.2% with placebo. Weight loss on the 2.4mg dose was still following a near-linear trajectory at week 48, suggesting the plateau had not yet been reached. Body composition analysis showed 78.1% of weight lost was fat mass, with only 21.9% lean mass loss — a ratio Altimmune describes as class-leading among GLP-1 class drugs. The liver fat data is where pemvidutide stands out most clearly. In the MASLD extension study, 24 weeks of treatment produced liver fat reductions of 56.3%, 75.2%, and 76.4% at the 1.2mg, 1.8mg, and 2.4mg doses. The IMPACT Phase 2b trial in biopsy-confirmed MASH patients (F2-F3 fibrosis) confirmed these effects, with 45.2% and 54.7% liver fat reductions at 1.2mg and 1.8mg at 24 weeks. These results position pemvidutide alongside survodutide as one of the most promising dual agonists for fatty liver disease. Pemvidutide uses Altimmune's proprietary EuPort domain technology, which binds albumin to extend the half-life for weekly dosing and slows entry into the bloodstream, potentially improving GI tolerability. Clinical development is ongoing with Phase 2b/3 trials planned.